This article gives an overview of the medications for cystic fibrosis. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are a class of medications that help improve the ...

RCT-2100 is under clinical development by Recode Therapeutics and currently in Phase II for Cystic Fibrosis. According to GlobalData, Phase II drugs for Cystic Fibrosis have a 31% phase transition ...

Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

combined groups: −5.4 mV (p < 0.001) CF = cystic fibrosis; FEV 1 = forced expiratory volume in 1 second. The classes of cystic fibrosis transmembrane conductance regulator (CFTR) mutations.

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis ...

Alyftrek is Vertex's fifth CFTR modulator to secure FDA approval. It is also under regulatory review in the European Union, the United Kingdom, Canada, Switzerland, Australia and New Zealand. Write to ...

- In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV 1 and further decreased sweat chloride compared to TRIKAFTA ® - BOSTON, December 20, 2024--(BUSINESS WIRE)--Vertex ...

Vertex Pharmaceuticals has secured two simultaneous US Food and Drug Administration (FDA) approvals for cystic fibrosis (CF) treatments, but both therapies come with boxed warnings for potential ...

Alyftrek combines vanzacaftor, tezacaftor and deutivacaftor and is the fifth cystic fibrosis transmembrane conductance regulator (CFTR) modulator from Vertex. The FDA approval covers patients who ...

TRIKAFTA, a combination of elexacaftor, tezacaftor, and ivacaftor, is designed to enhance the function of the defective protein caused by cystic fibrosis transmembrane conductance regulator (CFTR) ...

The Business Journal has the list of the Massachusetts biotech companies that raised the largest venture capital rounds in the last year. Meet the most-capitalized companies of 2024.